RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report

Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant (AD) condition with very high penetrance and expressivity. It is characterized into three clinical entities recognized as MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC). In both MEN2A and MEN2B, there is a manifestation of multicentric tumor formation in the major organs such as the thyroid, parathyroid, and adrenal glands where the RET proto-oncogene is expressed. The FMTC form differs from MEN2A and MEN2B, since medullary thyroid carcinoma (MTC) is the only feature observed. In this present brief report, we demonstrate a collection of RET proto-oncogene genotype data from countries around the Mediterranean Basin with variable characteristics. As expected, a great extent of the Mediterranean RET proto-oncogene genotype data resemble the data reported globally. Most interestingly, higher frequencies are observed in the Mediterranean region for specific pathogenic RET variants as a result of local prevalence. The latter can be explained by founder effect phenomena. The Mediterranean epidemiological data that are presented herein are very important for domestic patients, their family members’ evaluation, and ultimately their treatment.

[1]  Daniel Wegmann,et al.  Ancient mitochondrial diversity reveals population homogeneity in Neolithic Greece and identifies population dynamics along the Danubian expansion axis , 2022, Scientific Reports.

[2]  O. Kohlbacher,et al.  Population Genetics and Signatures of Selection in Early Neolithic European Farmers , 2022, Molecular biology and evolution.

[3]  C. Benbassat,et al.  Clinical correlates of a large Israeli cohort of Cys 618 Arg RET mutation , 2022, Endocrine Abstracts.

[4]  Travis J. Struck,et al.  The genomic origins of the world’s first farmers , 2022, Cell.

[5]  J. Pasternak,et al.  Multiple endocrine neoplasia 2: an overview , 2022, Therapeutic advances in chronic disease.

[6]  A. Maia,et al.  Geographical Variation in the profile of RET Variants in Patients with Medullary Thyroid Cancer: A Comprehensive Review. , 2021, European journal of endocrinology.

[7]  T. Žagar,et al.  Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency , 2021, Croatian medical journal.

[8]  P. Soares,et al.  Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma , 2021, Journal of Endocrinological Investigation.

[9]  A. Barlier,et al.  Correction to: MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives , 2020, Endocrine.

[10]  T. Dwight,et al.  Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study , 2020, Endocrine connections.

[11]  T. Bruckner,et al.  Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center. , 2019, The Journal of clinical endocrinology and metabolism.

[12]  R. Ciampi,et al.  Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations , 2019, Genes.

[13]  M. Castellano,et al.  p.Ser891Ala RET gene mutations in medullary thyroid cancer: Phenotypical and genealogical characterization of 28 apparently unrelated kindreds and founder effect uncovering in Northern Italy , 2019, Human mutation.

[14]  P. Parrilla,et al.  Prophylactic thyroidectomy in multiple endocrine neoplasia 2 (MEN2) patients with the C634Y mutation: A long-term follow-up in a large single-center cohort. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  C. Bris,et al.  Metabolomics signatures of a subset of RET variants according to their oncogenic risk level. , 2019, Endocrine-related cancer.

[16]  A. Tabarin,et al.  Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. , 2019, The lancet. Diabetes & endocrinology.

[17]  S. Grozinsky-Glasberg,et al.  Bilateral Medullary Thyroid Carcinoma in a 3-Year-Old Female Patient with Multiple Endocrine Neoplasia 2A Syndrome Undergoing Prophylactic Thyroidectomy: Should Current Guidelines Be Revised? , 2018, European Thyroid Journal.

[18]  K. Lorenz,et al.  Geographic epidemiology of medullary thyroid cancer families: unearthing European ancestral heritage. , 2018, Endocrine-related cancer.

[19]  G. Tanteles,et al.  Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect , 2018, Journal of Endocrinological Investigation.

[20]  V. Rohmer,et al.  Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers. , 2017, Thyroid : official journal of the American Thyroid Association.

[21]  T. Bruckner,et al.  Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon‐specific penetrance and changes in management during the last four decades , 2017, Clinical endocrinology.

[22]  E. Anagnostou,et al.  Familial MTC with RET exon 8 Gly533Cys mutation: origin and prevalence of second malignancy , 2017, Endocrine connections.

[23]  K. Mazaz,et al.  Bilateral pheochromocytoma with ganglioneuroma component associated with multiple neuroendocrine neoplasia type 2A: a case report , 2017, Journal of Medical Case Reports.

[24]  L. Mulligan,et al.  A comprehensive review on MEN2B. , 2017, Endocrine-related cancer.

[25]  L. L. Cunha,et al.  Evidence for the founder effect of RET533 as the common Greek and Brazilian ancestor spreading multiple endocrine neoplasia 2A. , 2017, European journal of endocrinology.

[26]  V. Zadnik,et al.  Cancer burden in slovenia with the time trends analysis , 2017, Radiology and oncology.

[27]  M. Carmo-Fonseca,et al.  A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A , 2016, Hormones.

[28]  M. E. Ertörer,et al.  Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey , 2016, Journal of clinical research in pediatric endocrinology.

[29]  D. Glavač,et al.  The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes. , 2015, Experimental and molecular pathology.

[30]  D. Reich,et al.  Genome-wide patterns of selection in 230 ancient Eurasians , 2015, Nature.

[31]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[32]  P. Vitti,et al.  Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? , 2015, Clinical endocrinology.

[33]  N. Nikolac,et al.  RET M918T-exon 16 mutation in subjects with sporadic medullary thyroid cancer (sMTC) , 2015 .

[34]  D. Berker,et al.  Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family , 2015, Journal of Endocrinological Investigation.

[35]  K. Saltiki,et al.  Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades. , 2015, European journal of endocrinology.

[36]  C. Lamas,et al.  RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. , 2015, European journal of endocrinology.

[37]  R. Domingues,et al.  Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma , 2015, Endocrine.

[38]  P. Morrison,et al.  Epidemiology, clinical features, and genetics of multiple endocrine neoplasia type 2B in a complete population. , 2014, The oncologist.

[39]  J. Blangero,et al.  Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility , 2014, Endocrine-related cancer.

[40]  J. Stamatoyannopoulos,et al.  Maritime route of colonization of Europe , 2014, Proceedings of the National Academy of Sciences.

[41]  L. Mulligan.  RET revisited: expanding the oncogenic portfolio , 2014, Nature Reviews Cancer.

[42]  J. Cerutti,et al.  Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: An appraisal of p.Y791 F and p.C634Y RET mutations in five unrelated Brazilian families , 2013, Journal of Endocrinological Investigation.

[43]  C. Sekulla,et al.  Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. , 2013, European journal of endocrinology.

[44]  M. Alevizaki,et al.  2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer , 2012, European Thyroid Journal.

[45]  B. Vlassopoulou,et al.  High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece , 2012, Clinical endocrinology.

[46]  V. Trovisco,et al.  In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. , 2011, Endocrine-related cancer.

[47]  C. Deltas,et al.  RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2 , 2011, Journal of endocrinological investigation.

[48]  A. Tabarin,et al.  Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. , 2011, The Journal of clinical endocrinology and metabolism.

[49]  A. Pinchera,et al.  Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. , 2010, European journal of endocrinology.

[50]  A. Barlier,et al.  RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience. , 2009, Journal of cancer research and therapeutics.

[51]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[52]  R. Domingues,et al.  Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas , 2009, British Journal of Cancer.

[53]  T. Economopoulos,et al.  Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. , 2008, European journal of endocrinology.

[54]  C. Eng,et al.  Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. , 2008, Endocrine-related cancer.

[55]  P. Parrilla,et al.  Pheochromocytoma in MEN 2A Syndrome. Study of 54 Patients , 2008, World Journal of Surgery.

[56]  J. Moley,et al.  Pheochromocytoma penetrance varies by RET mutation in MEN 2A. , 2007, Surgery.

[57]  C. Benbassat,et al.  Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. , 2007, Thyroid : official journal of the American Thyroid Association.

[58]  D. Yannoukakos,et al.  A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. , 2007, Hormones.

[59]  C. Carcassi,et al.  RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. , 2007, Thyroid : official journal of the American Thyroid Association.

[60]  D. Glavač,et al.  Hereditary medullary thyroid cancer in Slovenia – genotype-phenotype correlations , 2006, Wiener klinische Wochenschrift.

[61]  M. Lacerda,et al.  Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto‐oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal , 2006, Clinical endocrinology.

[62]  D. Yannoukakos,et al.  A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening , 2006, Clinical endocrinology.

[63]  M. Ruíz-Ferrer,et al.  Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients. , 2006, International journal of molecular medicine.

[64]  T. Passalaris,et al.  Description of the first two seemingly unrelated Greek Cypriot families with a common C618R RET proto-oncogene mutation. , 2004, Genetic testing.

[65]  B. Nilsson,et al.  Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618 , 2004, The British journal of surgery.

[66]  J. Cerutti,et al.  A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[67]  A. Maia,et al.  RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. , 2003, The Journal of clinical endocrinology and metabolism.

[68]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[69]  J. Benítez,et al.  High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain , 1999, Journal of medical genetics.

[70]  P. Parrilla,et al.  Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma , 1998, Clinical endocrinology.

[71]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[72]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[73]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[74]  C. Lamas,et al.  RET Cys 634 Arg mutation confers a more aggressive multiple endocrine neoplasia type 2 A phenotype than Cys 634 Tyr mutation , 2015 .

[75]  M. Alevizaki,et al.  2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer , 2012, European Thyroid Journal.

[76]  R. Domingues,et al.  Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. , 2007, Surgery.

[77]  R. Domingues,et al.  MEN 2A families: from hot spots to hot regions. , 2003, International journal of molecular medicine.

[78]  A. Biton,et al.  Cys 618 Arg mutation in the RET proto‐oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting , 1997, Human mutation.